Download PDF
Horm Metab Res 2015; 47(10): 773-778
DOI: 10.1055/s-0035-1555762
Review

Current Insights into the Pathogenesis of Graves’ Ophthalmopathy

R. S. Bahn
1   Mayo Clinic College of Medicine, Rochester, MN, USA
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Environmental, genetic, and immune factors are at play in the development of the variable clinical manifestations of Graves’ ophthalmopathy (GO). Among the environmental contributions, smoking is the risk factor most consistently linked to the development or worsening of the disease. The close temporal relationship between the diagnoses of Graves’ hyperthyroidism and GO have long suggested that these 2 autoimmune conditions may share pathophysiologic features. The finding that the thyrotropin receptor (TSHR) is expressed in orbital fibroblasts, the target cells in GO, supported the notion of a common autoantigen. Both cellular and humeral immunity directed against TSHR expressed on orbital fibroblasts likely initiate the disease process. Activation of helper T cells recognizing TSHR peptides and ligation of TSHR by TRAb lead to the secretion of inflammatory cytokines and chemokines, and enhanced hyaluronic acid (HA) production and adipogenesis. The resulting connective tissue remodeling results in varying degrees extraocular muscle enlargement and orbital fat expansion. A subset of orbital fibroblasts express CD34, are bone-marrow derived, and circulate as fibrocytes that infiltrate connective tissues at sites of injury or inflammation. As these express high levels of TSHR and are capable of producing copious cytokines and chemokines, they may represent an orbital fibroblast population that plays a central role in GO development. In addition to TSHR, orbital fibroblasts from patients with GO express high levels of IGF-1R. Recent studies suggest that these receptors engage in cross-talk induced by TSHR ligation to synergistically enhance TSHR signaling, HA production, and the secretion of inflammatory mediators.

Key words

Graves’ disease - thyroid stimulating hormone - TSH-receptor antibodies - IGF-1


Publication History

Received: 30 January 2015

Accepted: 01 June 2015

Article published online:
11 September 2015

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726-738
    CrossrefPubMedGoogle Scholar
  • 2 Wiersinga WM. Management of Graves ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007; 3: 396-404
    CrossrefPubMedGoogle Scholar
  • 3 Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747-793
    PubMedGoogle Scholar
  • 4 Tellez M, Cooper J, Edmonds C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992; 36: 291-294
    CrossrefPubMedGoogle Scholar
  • 5 Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid 2010; 20: 715-725
    CrossrefPubMedGoogle Scholar
  • 6 Yin X, Latif R, Bahn R, Tomer Y, Davies TF. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves’ ophthalmopathy. Thyroid 2008; 18: 1201-1206
    CrossrefPubMedGoogle Scholar
  • 7 Yin X, Latif R, Bahn R, Davies TF. Genetic profiling in Graves’ disease: further evidence for lack of a distinct genetic contribution to Graves’ ophthalmopathy. Thyroid 2012; 22: 730-736
    CrossrefPubMedGoogle Scholar
  • 8 Hasham A, Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res 2012; 54: 204-213
    CrossrefPubMedGoogle Scholar
  • 9 Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12: 855-860
    CrossrefPubMedGoogle Scholar
  • 10 Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94: 3700-3707
    CrossrefPubMedGoogle Scholar
  • 11 Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol 1996; 45: 477-481
    CrossrefPubMedGoogle Scholar
  • 12 Krassas GE, Segni M, Wiersinga WM. Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005; 153: 515-521
    CrossrefPubMedGoogle Scholar
  • 13 Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92: 59-64
    CrossrefPubMedGoogle Scholar
  • 14 Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994; 40: 67-72
    CrossrefPubMedGoogle Scholar
  • 15 Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992; 326: 1733-1738
    CrossrefPubMedGoogle Scholar
  • 16 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73-78
    CrossrefPubMedGoogle Scholar
  • 17 Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75
    CrossrefPubMedGoogle Scholar
  • 18 Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009; 94: 3381-3386
    CrossrefPubMedGoogle Scholar
  • 19 Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 2005; 90: 5321-5323
    CrossrefPubMedGoogle Scholar
  • 20 Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-1352
    CrossrefPubMedGoogle Scholar
  • 21 Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol 1995; 268: C382-C388
    CrossrefPubMedGoogle Scholar
  • 22 Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646
    CrossrefPubMedGoogle Scholar
  • 23 Pappa A, Calder V, Ajjan R, Fells P, Ludgate M, Weetman AP, Lightman S. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 1997; 109: 362-369
    CrossrefPubMedGoogle Scholar
  • 24 Eckstein AK, Quadbeck B, Tews S, Mann K, Kruger C, Mohr CH, Steuhl KP, Esser J, Gieseler RK. Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression. Br J Ophthalmol 2004; 88: 803-808
    CrossrefPubMedGoogle Scholar
  • 25 Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 776-780
    PubMedGoogle Scholar
  • 26 Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthal Vis Sci 2014; 55: 1735-1748
    CrossrefPubMedGoogle Scholar
  • 27 Feldon SE, Park DJ, O’Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 2005; 46: 3913-3921
    CrossrefPubMedGoogle Scholar
  • 28 Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G. Retrobulbar T cells from patients with Graves’ ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994; 93: 2738-2743
    CrossrefPubMedGoogle Scholar
  • 29 Otto E, Forster G, Kuhlemann K, Hansen C, Kahaly GJ. TSH receptor in endocrine autoimmunity. Clin Exp Rheumatol 1996; 14 (Suppl. 15) S77-S84
    PubMedGoogle Scholar
  • 30 Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’disease and ophthalmopathy. Endo Rev 2003; 24: 802-835
    CrossrefPubMedGoogle Scholar
  • 31 Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002; 87: 385-392
    CrossrefPubMedGoogle Scholar
  • 32 Peng H, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol 2012; 12: 491-496
    CrossrefPubMedGoogle Scholar
  • 33 Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol 2015; 11: 171-181
    CrossrefPubMedGoogle Scholar
  • 34 Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2010; 95: 430-438
    CrossrefPubMedGoogle Scholar
  • 35 Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest 1988; 11: 615-619
    CrossrefPubMedGoogle Scholar
  • 36 Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 2000; 10: 1093-1100
    CrossrefPubMedGoogle Scholar
  • 37 Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 2000; 52: 267-271
    CrossrefPubMedGoogle Scholar
  • 38 Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123-2131
    CrossrefPubMedGoogle Scholar
  • 39 Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470
    CrossrefPubMedGoogle Scholar
  • 40 Heufelder AE, Bahn RS. Evidence for the presence of a functional TSH-receptor in retroocular fibroblasts from patients with Graves’ ophthalmopathy. Exp Clin Endocrinol 1992; 100: 62-67
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet 1993; 342: 337-338
    CrossrefPubMedGoogle Scholar
  • 42 Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998-1002
    PubMedGoogle Scholar
  • 43 Ludgate M, Crisp M, Lane C, Costagliola S, Vassart G, Weetman A, Daunerie C, Many MC. The thyrotropin receptor in thyroid eye disease. Thyroid 1998; 8: 411-413
    CrossrefPubMedGoogle Scholar
  • 44 Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab 1997; 82: 2003-2005
    CrossrefPubMedGoogle Scholar
  • 45 Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol 2003; 58: 280-287
    CrossrefPubMedGoogle Scholar
  • 46 Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinol 2009; 150: 519-529
    CrossrefPubMedGoogle Scholar
  • 47 Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab 2013; 98: 2153-2159
    CrossrefPubMedGoogle Scholar
  • 48 Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem 2009; 284: 26447-26455
    CrossrefPubMedGoogle Scholar
  • 49 Kumar S, Nadeem S, Stan MS, Coenen MJ, Bahn RS. A stimulatory thyrotropin receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol 2011; 46: 155-163
    CrossrefPubMedGoogle Scholar
  • 50 Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves’ orbital fibroblasts: Inhibition by an IGF-1 receptor blocking antibody. J Clin Endocrinol Metab 2012; 97: 1681-1687
    CrossrefPubMedGoogle Scholar
  • 51 Petersen JC, Kaiser S, Dean N, Simoncig A, Liu HY, Cavalieri AL, Cacho C, Turcu IC, Springate E, Frassetto F, Poletto L, Dhesi SS, Berger H, Cavalleri A. Clocking the melting transition of charge and lattice order in 1T-TaS2 with ultrafast extreme-ultraviolet angle-resolved photoemission spectroscopy. Phys Rev Lett 2011; 107: 177402
    CrossrefPubMedGoogle Scholar
  • 52 Moshkelgosha S, So PW, Deasy N, Diaz-Cano S, Banga JP. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves’ orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinol 2013; 154: 3008-3015
    CrossrefPubMedGoogle Scholar
  • 53 Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168: 2789-2794
    CrossrefPubMedGoogle Scholar
  • 54 Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?. J Clin Endocrinol Metab 2011; 96: 2386-2394
    CrossrefPubMedGoogle Scholar
  • 55 Pyne NJ, Pyne S. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow?. Trend Pharmacol Sci 2011; 32: 443-450
    CrossrefPubMedGoogle Scholar
  • 56 Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?. Pharmacol Rev 2010; 62: 199-236
    CrossrefPubMedGoogle Scholar
  • 57 LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163
    CrossrefPubMedGoogle Scholar
  • 58 Riedemann J, Macaulay VM. IGF1R signaling and its inhibition. Endocr Relat Cancer 2006; 13 (Suppl. 01) S33-S43
    CrossrefPubMedGoogle Scholar
  • 59 Aubin D, Gagnon A, Sorisky A. Phosphoinositide 3-kinase is required for human adipocyte differentiation in culture. Int J Obes (Lond) 2005; 29: 1006-1009
    CrossrefPubMedGoogle Scholar
  • 60 Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 2008; 181: 4397-4405
    CrossrefPubMedGoogle Scholar
  • 61 Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993; 16: 251-257
    CrossrefPubMedGoogle Scholar
  • 62 Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170: 6348-6354
    CrossrefPubMedGoogle Scholar
  • 63 Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004; 89: 5076-5080
    CrossrefPubMedGoogle Scholar
  • 64 Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170: 6348-6354
    CrossrefPubMedGoogle Scholar
  • 65 Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC. Bidirectional TSH and IGF-1 receptor cross-talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab 2015; 100: 1071-1077
    CrossrefPubMedGoogle Scholar
  • 66 Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Kohrle J, Eckstein A, Schomburg L. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab 2013; 98: 752-760
    CrossrefPubMedGoogle Scholar
  • 67 Neumann S, Kleinau G, Costanzi S, Moore S, Jiang JK, Raaka BM, Thomas CJ, Krause G, Gershengorn MC. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinol 2008; 149: 5945-5950
    CrossrefPubMedGoogle Scholar
  • 68 Neumann S, Nir EA, Eliseeva E, Huang W, Marugan J, Xiao J, Dulcey AE, Gershengorn MC. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinol 2014; 155: 310-314
    CrossrefPubMedGoogle Scholar
  • 69 Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 2015; 100: 432-441
    CrossrefPubMedGoogle Scholar
  • 70 Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate-severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015; 100: 422-431
    CrossrefPubMedGoogle Scholar